Gilead Sciences Inc. (NYSE: GILD) is scheduled to report second quarter 2019 earnings results on Tuesday, July 30, after market close. Analysts have forecast earnings of $1.72 per share on revenue of $5.51 billion.
Gilead’s top line results are expected to benefit from strength in the HIV product segment with momentum from Biktarvy in particular. HCV product sales are likely to see weakness, continuing the same trend as last quarter. Products like Odefsey, Vemlidy and Yescarta are likely to continue their growth trends in the second quarter.
Another area to watch is the company’s updates on its pipeline. Gilead is working on expanding the use of Descovy and Biktarvy in the treatment of HIV. The company also intends to file a new drug application for the approval of filgotinib in the treatment of rheumatoid arthritis. Gilead has entered into research partnerships with various companies for several products and updates on these alliances are also worth watching.
In the first quarter of 2019, Gilead topped market estimates. Revenues grew nearly 4% year-over-year to $5.3 billion while adjusted EPS rose 19% to $1.76. Sales in HIV Products grew 14% while sales in HCV Products dropped 24%. Sales of Other Products also fell 7%.
For fiscal year 2019, the company estimates its product sales to come in the range of $21.3 billion to $21.8 billion and adjusted product gross margin to come in the range of 85% to 87%.
Shares of Gilead have gained 9% so far this year and more than 3% over the past three months. The stock was up 0.91% during morning trade on Monday.
Most Popular
What to look for when CVS Health (CVS) reports Q3 earnings
Healthcare company CVS Health Corporation (NYSE: CVS) is all set to report earnings next week, with Wall Street expecting a mixed outcome. The company has been facing challenges in certain
eBay (EBAY): A few factors that helped drive growth in Q3 2024
Shares of eBay Inc. (NASDAQ: EBAY) stayed green on Friday. The stock has gained 32% year-to-date. The ecommerce leader delivered revenue and earnings growth for the third quarter of 2024,
CVX Earnings: Chevron reports lower revenue and profit for Q3 2024
Energy exploration company Chevron Corporation (NYSE: CVX) on Friday announced third-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation dropped to